{"disease":{"id":"advanced-head-and-neck-squamous-cell-carcinoma","name":"advanced head and neck squamous cell carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04949503","title":"A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN","phase":"","overall_status":"COMPLETED","enrollment_count":1931,"lead_sponsor_name":"Biotech Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05050162","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":1714,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06129864","title":"A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1145,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04892173","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Johnson & Johnson Enterprise Innovation Inc.","has_results":false},{"nct_id":"NCT07524452","title":"Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04215978","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT03117257","title":"Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":144,"lead_sponsor_name":"Guiyang Medical University","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03196869","title":"the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Guiyang Medical University","has_results":false},{"nct_id":"NCT03426657","title":"Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT06470217","title":"Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT06240689","title":"A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05635643","title":"Study of CHS-114 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Coherus Oncology, Inc.","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03666273","title":"Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07369882","title":"Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Qunxing Li,MD","has_results":false},{"nct_id":"NCT03684785","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Exicure, Inc.","has_results":false},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04442126","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Numab Therapeutics AG","has_results":true},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05172245","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07379424","title":"A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":37,"lead_sponsor_name":"chen chao Professor","has_results":false},{"nct_id":"NCT03841110","title":"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT06537011","title":"AK112 Plus AP Regimen for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03590054","title":"Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Rahul Aggarwal","has_results":false},{"nct_id":"NCT03254927","title":"A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Celldex Therapeutics","has_results":true},{"nct_id":"NCT07094685","title":"Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT05057247","title":"Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Glenn J. Hanna","has_results":true},{"nct_id":"NCT05861557","title":"Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":23,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT07310771","title":"Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07371234","title":"Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Xiwei XU","has_results":false},{"nct_id":"NCT06580054","title":"Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT04533750","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04454489","title":"Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT05233436","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04106167","title":"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04947241","title":"Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04733495","title":"Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}